training

7 recommendations to increase training consistency for patients self-injecting biologics

By Bill Guilliouma | September 9, 2021
Posted in , , , , ,

Biologic drugs are finding growing success in addressing chronic diseases — from diabetes and rheumatoid arthritis to multiple sclerosis and Crohn’s. A significant rise in self-injection therapies is contributing to… Read More »

Supporting Patients During Treatment

By Bill Guilliouma | August 24, 2021
Posted in , , , , , ,

We speak with Adam Shain, Director Business Development, Digital Healthcare, and Josh Hopkins, Program Manager, AdhereIT about the AdhereIT 360 Base and AdhereIT Clip – a runner up for The… Read More »

Noble Launches Human Factors Engineering Services to Support Product Development and US FDA Approval of Medical Devices and Combination Products

By Bill Guilliouma | February 2, 2021
Posted in , , , ,

“Human Factors Plus” (HF+) is a natural extension of Noble’s deep understanding of the patient experience when it comes to self-administering drug therapies ORLANDO, Fla. (February 2, 2021) – Noble,… Read More »

Training Devices & Patient Education Play A Crucial Role in The Self-Injection Drug Delivery Market

By Bill Guilliouma | October 27, 2020
Posted in , , , , , ,

The biopharmaceutical industry has experienced incredible exponential growth in recent decades. Annual revenues have increased from US$4.4 billion (ÂŁ3.4 billion) in 1990 to $275 billion (ÂŁ213 billion) in 2018 (a… Read More »

Noble and Aptar Pharma Launch AdhereIT®, a Connected Medical Device Solution for Disease Management, Adherence and Onboarding Patients

By Bill Guilliouma | October 5, 2020
Posted in , , , , , , , , ,

Crystal Lake, Illinois and Orlando, Florida (October 5, 2020) — Noble and Aptar Pharma are pleased to announce the launch of AdhereIT® — a connected, intuitive and user-friendly onboarding solution… Read More »

AdhereIT 360 Base Demonstration Video

By Bill Guilliouma | October 1, 2020
Posted in , , , , , , , ,

AdhereIT 360 Base Demonstration Video: